National Institutes of Health, Paradigm Genetics, TissueInformatics, BioTrove, Sumitomo, Oxford Finance, Beckman Coulter, IntegraGen, Aventis, San Diego State, Invitrogen, Pfizer, CardioDynamics, Gen-Probe, Abbott, Caprion | GenomeWeb

NIH to See Mild Increase in FY 2005; Mad Cow Programs to Jump Nearly 40 Percent

The National Institutes of Health will have around 2.6 percent more money to spend in fiscal year 2005 than it had in fiscal 2004 if the US Congress approves President Bush’s budget, the Office of Management and Budget reported this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.